Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG-350A in combination with chemoradiotherapy in locally advanced rectal cancer
NCT06459869Phase 1Active, not recruiting
- Sponsor
- Akamis Bio
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of NG-350A in rectal cancer, sponsored by Akamis Bio. Primary endpoint: Proportion of patients achieving a response (ncCR / cCR) at 12 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
NG-350A
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06459869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06459869.